381 related articles for article (PubMed ID: 29498449)
1. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
Tozbikian GH; Zynger DL
Breast J; 2018 Jul; 24(4):535-540. PubMed ID: 29498449
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
McLemore LE; Albarracin CT; Gruschkus SK; Bassett RL; Wu Y; Dhamne S; Yim I; Lin K; Bedrosian I; Sneige N; Chen H
Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
[TBL] [Abstract][Full Text] [Related]
3. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
5. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM; Ebel JJ; Zhao W; Zynger DL
Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
[TBL] [Abstract][Full Text] [Related]
6. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
[TBL] [Abstract][Full Text] [Related]
7. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
8. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
9. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
10. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
11. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
13. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract][Full Text] [Related]
15. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
16. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
17. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
Dabbs DJ; Klein ME; Mohsin SK; Tubbs RR; Shuai Y; Bhargava R
J Clin Oncol; 2011 Nov; 29(32):4279-85. PubMed ID: 21990395
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
[TBL] [Abstract][Full Text] [Related]
19. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
20. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
